Abiomed, Inc.ABMDNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR+6.1%
5Y CAGR-4.0%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+6.1%/yr
vs +6.8%/yr prior
5Y CAGR
-4.0%/yr
Recent acceleration
Acceleration
-0.7pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202226.72%
2021-2.17%
20206.24%
201922.39%
201820.44%
201732.81%
201630.65%
201517.23%
201427.34%
201317.45%